BRAVA and External Breast Expansion Before Fat Grafting: What the Suction Domes Were Supposed to Do, What the Studies Showed, and Why So Few Surgeons Still Use Them

The patient wanted a cup size and no implants, and the consultation seemed to promise both. Fat would come from the abdomen and thighs, which they were glad to lose. The catch was the month before surgery. They would wear a pair of hard plastic domes over the breasts, sealed at the edges and connected to a small pump, for most of every night and part of every weekend. The domes would pull steadily on the tissue and, the coordinator explained, make room for more fat to survive. By the second week the skin under the rims was raw. By the third, they were wearing the device for half the prescribed hours and feeling guilty about it. The surgery went ahead. A year later they had gained less than they had hoped, and they could not tell whether that was the fat, the technique, or the nights they had skipped.

That story is a fair summary of external breast pre-expansion as most patients experienced it. The concept was not a gimmick. It came from a serious problem in fat grafting, it was developed and published by surgeons with real academic credentials, and the strongest results reported with it were genuinely impressive. The trouble was everything between the concept and the result: a demanding regimen, a modest and mostly single-group evidence base, and a gap between the outcomes in the published series and the outcomes most practices could reproduce.

This piece explains the device and the reasoning behind it, what the studies showed and how much weight they can bear, why the regimen is so hard to follow, and where pre-expansion still has a reasonable claim to a place, which is mostly in reconstruction rather than cosmetic enlargement.

What BRAVA is, and how a nonsurgical enlargement device became a surgical tool

The short answer: BRAVA is a pair of semirigid domes with a cushioned silicone rim and a small pump that applies sustained, low-level suction to the breasts for hours at a time, first marketed as a way to enlarge the breasts without surgery and later repurposed to stretch and prepare the breast before large-volume fat grafting.

The device was developed in the 1990s by Dr. Roger Khouri, a Miami plastic surgeon with a background in microsurgery and tissue expansion. The underlying principle is old and well established in reconstructive surgery: living tissue placed under sustained tension grows. Surgeons have used internal tissue expanders, balloons inflated gradually beneath the skin, for decades to create extra skin for reconstruction, and the same biology is why the abdomen stretches in pregnancy. External expansion tried to get a similar effect from the outside, with suction instead of an inflated implant.

In its first incarnation, BRAVA was sold directly as a nonsurgical breast enhancement system. The regimen was punishing: many hours a day, every day, for months. Some users did see measurable gains, and a small early study reported them, but the effect was modest, the commitment was enormous, and a meaningful share of the enlargement receded once the device was set aside. As a stand-alone product it never became mainstream, and most plastic surgeons regarded it with polite skepticism.

The device found its second life in combination with fat grafting. By the late 2000s, fat transfer to the breast was moving from a fringe procedure to a recognized option, helped along by better harvesting and injection techniques and by the American Society of Plastic Surgeons fat graft task force, which concluded that breast fat grafting could be considered with appropriate caution, particularly around imaging. The basic mechanics of that operation, and the long timeline over which a grafted breast settles, are described in the piece on fat transfer breast augmentation and how the result matures.

Fat grafting to the breast had a ceiling problem. The amount of fat that would survive in a single session was limited, not by how much fat a patient had to give, but by how much the breast could accept. Khouri and colleagues argued that external expansion could raise that ceiling. Wear the domes for several weeks before surgery, the reasoning went, and the breast would arrive in the operating room larger, looser, and better supplied with blood, able to take a bigger graft without the graft dying. BRAVA was rebranded as a preparatory step, and the combination was marketed as a route to an implant-sized result without an implant.

The recipient-site problem, and why stretching the breast first was supposed to help

The short answer: transplanted fat survives only if it is close enough to living blood supply to be fed while new vessels grow in, and packing too much fat into a tight space raises the pressure in the tissue and starves the graft, so pre-expansion was meant to create a larger, looser, better vascularized space that could hold more fat at safe pressures.

Grafted fat arrives with no blood supply of its own. For the first several days, the cells survive by absorbing nutrients and oxygen from the surrounding tissue, and only the fat within a short distance of living tissue makes it to the point where new capillaries grow in. Fat deeper in a large clump starves, and dead fat becomes oil cysts, calcifications, or firm lumps. That biology is the reason surgeons inject fat in many thin threads rather than in a few large deposits, and it is laid out in detail in the piece on fat graft survival biology.

The breast adds a mechanical constraint. Injected fat takes up space, and in a breast with tight skin and dense tissue, there is only so much room before the pressure inside the tissue climbs. Khouri's group framed this as a recipient-site limit: past a certain point, adding more fat does not increase the result. It raises interstitial pressure, compresses the small vessels the graft depends on, and kills more of what was injected, so the surgeon spends more fat to get the same or a worse outcome. A small, firm breast in a patient with little skin laxity is the hardest case, because it has the least space to begin with.

External expansion was supposed to change the recipient site in three ways. First, the sustained pull would stretch the skin envelope and the internal framework of the breast, creating a larger space that could accept more fat before pressure became a problem. Second, the tension would stimulate new blood vessel growth, so the tissue receiving the graft would have more capillaries close to more of the fat. Third, the stretched tissue would act like a looser scaffold, with more surface area for fat to be distributed in thin layers rather than clumped. Animal work and imaging studies offered some support for each of these effects, and the logic was coherent enough that it persuaded many skeptics in principle.

The theory also explains why the device was paired with a particular surgical style. Pre-expansion was meant to be followed promptly by grafting, while the breast was still at its stretched peak, with fat placed widely and diffusely through the expanded space using many small passes. Delays between the last session in the domes and the operation would allow the tissue to recoil, losing part of the effect. Problems with that technique, including the lumps and necrosis that follow when fat is placed too densely, are covered in the piece on fat necrosis after fat transfer.

What the studies showed, and how far the numbers can be stretched

The short answer: the published series from the developers and a few early adopters reported fat retention well above what most surgeons see without pre-expansion, but those studies were small, mostly lacked a control group, often had close ties to the device, and lost a meaningful number of patients to the regimen, and independent groups have not reliably reproduced the headline results.

The strongest early evidence came from two sources. One was a prospective multicenter study led by Khouri and published in Plastic and Reconstructive Surgery in 2012, which followed patients who used BRAVA before fat grafting and reported durable volume gains with a low complication rate. The other was a study by Dr. Daniel Del Vecchio and Dr. Louis Bucky, published in the same journal in 2011, which used volumetric MRI before surgery and months afterward to measure how much grafted fat remained. Both reported retention figures that were striking compared with the general experience of breast fat grafting, and the MRI approach in particular was a methodological step forward, since a tape measure and a photograph are poor tools for measuring volume.

Those studies deserve credit for what they did, and caution about what they could not. Neither was a randomized trial comparing pre-expansion with grafting alone in otherwise similar patients. Both were conducted by surgeons who were deeply invested in the technique, and in the case of the device's inventor, financially connected to it. Patient selection mattered enormously: people willing and able to complete weeks of nightly suction are a self-selected group, likely more motivated and more consistent in every part of their care. And results reported by the most experienced hands in a field rarely transfer intact to the average practice.

"

The most impressive results reported with external expansion came from the people who invented the method and the patients who could tolerate it. That is a real finding, and it is not the same finding as "this works for most people."

"

Later work from other groups painted a more mixed picture. Some reported benefit, particularly in reconstruction and in patients with tight, small breasts. Others found that gains were smaller than advertised, that a substantial share of patients did not complete the protocol, or that improvements in technique alone, such as better processing of fat and more diffuse injection, closed much of the gap without a device. Systematic reviews of breast fat grafting have repeatedly noted that the literature is heterogeneous, with different measurement methods, follow-up times, and definitions of success, which makes it difficult to say with confidence how much pre-expansion adds on average.

There is also a measurement problem specific to this technique. The goal is to know what fraction of grafted fat survives. But the expanded breast is temporarily swollen by the device, the operation adds its own swelling, and the result settles over many months. A study that measures too early, or measures from the wrong baseline, can make retention look better or worse than it is. The value of volumetric MRI was that it could be repeated after the swelling resolved. The limitation was that relatively few patients in the overall literature were measured that way. Consumers comparing published success rates against marketing claims should keep in mind that phrases like "up to" and "as much as" usually describe the top of a range, a habit examined more broadly in the piece on "natural results" as a marketing phrase.

The compliance problem: hours in the domes, raw skin, and the patients who stop

The short answer: pre-expansion only works if the device is worn as prescribed, which typically means many hours a day for several weeks, and skin irritation, blistering, disrupted sleep, and the sheer inconvenience of the regimen cause many patients to wear it less than intended or abandon it entirely.

The protocol differs by surgeon, but the common features are demanding. The domes are worn for most of the night, and sometimes for added hours during the day, for several weeks before surgery. Some protocols use lower pressures for long periods and higher pressures in the days just before the operation. Many also call for the device to be worn for a period afterward, on the theory that continued gentle tension supports the graft while it takes. During all of that time, the domes are bulky enough to be visible under ordinary clothing and awkward to sleep in, particularly for side and stomach sleepers.

The skin is where the regimen most often breaks down. The rim of each dome presses on the same ring of skin for hours at a time, and that skin is also under suction. Redness and irritation are common. Blisters, superficial skin breakdown, and contact dermatitis from the rim material or adhesives occur often enough that protocols include skin care instructions and rest days. Patients with sensitive skin, a history of eczema, or thin skin on the upper chest tend to have the most trouble. When the skin breaks, the device has to come off until it heals, and the weeks of preparation are interrupted at exactly the time the regimen is supposed to be building toward surgery.

Then there is life. The device is incompatible with an active social calendar, with travel, with intimacy, and in many households with sleeping beside a partner who did not sign up for a pump. Shift workers, parents of small children, and anyone with a physically demanding job all struggle. Published series have reported that a meaningful fraction of patients either did not complete the protocol or wore the device for well below the prescribed time. A treatment that depends on hundreds of hours of patient effort tends to be judged in practice by the effort patients actually give, not the effort they were asked for, and that may be the single largest reason the method did not spread.

None of this replaces the usual risks of the operation itself. Fat grafting to the breast still involves liposuction at the donor sites, with the swelling, bruising, and contour risks that come with it, and it still produces oil cysts and calcifications in some patients. Those findings show up on mammograms and ultrasounds and occasionally prompt a biopsy to rule out cancer, which is why radiologists need to know about the grafting. The practicalities are covered in the piece on breast imaging after implants and fat transfer. There is no evidence that pre-expansion itself increases cancer risk, but it does not reduce the imaging considerations that come with any breast fat graft.

Where pre-expansion still makes sense, and the alternatives most surgeons choose instead

The short answer: the strongest remaining case for external expansion is in reconstruction, especially fat-based reconstruction after mastectomy or in tight, scarred, or irradiated tissue, while for cosmetic enlargement most surgeons now rely on careful grafting without a device, staged sessions, or implants.

Reconstruction is where the recipient-site problem is most severe and where the payoff from a larger, better supplied bed is highest. After mastectomy, the chest wall can be thin and tight, and radiation leaves tissue scarred and poorly vascularized. Khouri and others reported building breasts with fat alone over several sessions, using external expansion between procedures, in patients who did not want or could not tolerate an implant or a flap. Those cases are demanding and require many operations, but for a patient who has ruled out the alternatives, the trade-off can be reasonable. The broader landscape of options is outlined in the piece on breast reconstruction after mastectomy.

Some surgeons have also used expansion for congenital conditions where the breast is tight and constricted, such as the tuberous breast, where the base is narrow and the lower pole is short, described in the piece on tuberous breast deformity. It has been used to address asymmetry, where only one side needs volume, a problem covered in the piece on facial and breast asymmetry. And it has been offered to patients having implants removed who want some volume restored with fat, a scenario discussed in the piece on skin retraction after breast implant removal. In each case, the argument is the same: a tight space benefits from being stretched before it is filled.

For cosmetic augmentation in a healthy breast, the field has largely moved on. Many surgeons who perform fat transfer to the breast now aim for a modest gain, often around a cup size or less, using refined harvesting and processing and diffuse injection, without any device. If more volume is wanted, they schedule a second grafting session months later, after the first has settled. That approach trades one long preparation for two operations, but it avoids the regimen and its dropout problem. The realistic ceiling of fat-only augmentation, and how it compares with implants, is covered in the piece on fat transfer as a natural alternative to implants.

Other patients end up with implants after all, sometimes combined with a thin layer of fat to soften edges and reduce rippling, an approach often called composite or hybrid augmentation. For them, the decisions shift to device choice, as covered in the piece on saline versus silicone implants, and to sizing, discussed in the piece on how surgeons decide implant size. An implant gives a predictable volume in a single operation. Fat gives a softer and more variable result that may take more than one session. External expansion was an attempt to make fat behave more like an implant, and for most cosmetic patients that attempt has given way to accepting fat for what it is.

Availability is another practical issue. The device's commercial history has been uneven, and whether it is currently supplied, supported, and used by a given practice varies. A patient told that pre-expansion is part of the plan should ask whether the surgeon uses it routinely, how many patients have completed the regimen, and what the practice does if a patient cannot tolerate it.

A useful measure of a consultation is whether the surgeon volunteers the regimen's difficulty and the limits of the evidence, or presents the device as a simple add-on. The same applies to any adjunct marketed as boosting fat survival, including stem cell enrichment, whose regulatory status is covered in the piece on stem cell claims in aesthetic surgery. When the stakes are high and the plan depends on an unusual regimen, a second consultation is a reasonable investment.

The honest summary

External breast pre-expansion was built on sound biology. Fat grafts die when they are crowded into tight, poorly supplied tissue, and stretching that tissue in advance should, in principle, let more fat survive. The developers and a few early adopters reported results that justified the excitement, and their use of MRI to measure retention raised the standard for the field.

What the method never established was that its top results were typical. The studies were small and mostly uncontrolled, the investigators were invested in the outcome, and the patients who completed the regimen were a self-selected group. The regimen itself, weeks of nightly suction with frequent skin problems, was more than many patients could manage, and the benefit of a device depends on wearing it.

For most people considering cosmetic fat transfer to the breast today, the realistic choices are a modest gain from careful grafting, a staged series of grafting sessions, or an implant, with or without fat added for softness. External expansion retains a more defensible role in reconstruction and in tight, constricted, or scarred breasts, where the recipient-site problem is severe and the alternatives are limited. A patient offered the device should ask what the surgeon's own patients have achieved, how many finished the regimen, and what the plan is if they cannot. The answers say more about whether it belongs in a particular plan than any published retention figure.